FendX Announces Publication of Results of Its Pathogen Detection Nanotechnology
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has announced the publication of research results demonstrating its AI-enhanced nanotechnology's ability to detect bacterial contamination on surfaces with 96.7% accuracy. The study, conducted at McMaster University, was peer-reviewed and published in 'Advanced Functional Materials' on July 30, 2024.
The technology, derived from FendX's licensed nanotechnology, incorporates a color-changing surface coating that transitions from blue to green-yellow to indicate bacterial biofilm formation. Using AI machine learning, it achieves 100% sensitivity and 95% accuracy in contamination detection.
Carolyn Myers, President and CEO of FendX, highlighted the potential of this technology for infection prevention and control in healthcare settings. The company also announced the resignation of Andrea Mulder as COO, effective August 30, 2024.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) ha annunciato la pubblicazione dei risultati di ricerca che dimostrano la capacità della sua nanotecnologia migliorata dall'IA di rilevare la contaminazione batterica sulle superfici con un'accuratezza del 96,7%. Lo studio, condotto presso la McMaster University, è stato sottoposto a revisione paritaria ed è stato pubblicato in 'Advanced Functional Materials' il 30 luglio 2024.
La tecnologia, derivata dalla nanotecnologia concessa in licenza da FendX, incorpora un rivestimento superficiale che cambia colore e passa da blu a verde-giallo per indicare la formazione di biofilm batterici. Utilizzando l'apprendimento automatico dell'IA, raggiunge 100% di sensibilità e 95% di accuratezza nella rilevazione della contaminazione.
Carolyn Myers, Presidente e CEO di FendX, ha sottolineato il potenziale di questa tecnologia per la prevenzione e il controllo delle infezioni negli ambienti sanitari. L'azienda ha inoltre annunciato le dimissioni di Andrea Mulder come COO, con effetto dal 30 agosto 2024.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) ha anunciado la publicación de los resultados de investigación que demuestran la capacidad de su nanotecnología mejorada con IA para detectar contaminación bacteriana en superficies con una precisión del 96,7%. El estudio, realizado en la Universidad McMaster, fue revisado por pares y publicado en 'Advanced Functional Materials' el 30 de julio de 2024.
La tecnología, derivada de la nanotecnología licenciada de FendX, incorpora un recubrimiento superficial que cambia de color, pasando de azul a verde-amarillo para indicar la formación de biofilm bacteriano. Usando el aprendizaje automático de IA, logra 100% de sensibilidad y 95% de precisión en la detección de contaminaciones.
Carolyn Myers, Presidenta y CEO de FendX, destacó el potencial de esta tecnología para la prevención y control de infecciones en entornos de atención médica. La empresa también anunció la renuncia de Andrea Mulder como COO, efectiva a partir del 30 de agosto de 2024.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)는 96.7%의 정확도로 표면에서 박테리아 오염을 감지할 수 있는 AI 기반 나노기술의 연구 결과 발표를 발표했습니다. 이 연구는 맥마스터 대학교에서 수행되었으며 동료 검토를 거쳐 2024년 7월 30일 'Advanced Functional Materials'에 발표되었습니다.
FendX의 라이센스 나노기술에서 파생된 이 기술은 색상이 변하는 표면 코팅을 포함하고 있으며, 박테리아 바이오필름 형성을 나타내기 위해 파란색에서 녹색-노란색으로 변합니다. AI 머신 러닝을 사용하여 오염 감지에서 100%의 민감도와 95%의 정확도를 달성합니다.
FendX의 사장 겸 CEO인 Carolyn Myers는 의료 환경에서 감염 예방 및 통제를 위한 이 기술의 잠재력을 강조했습니다. 회사는 또한 2024년 8월 30일부로 COO Andrea Mulder의 사임을 발표했습니다.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) a annoncé la publication des résultats de recherche démontrant la capacité de sa nanotechnologie améliorée par IA à détecter la contamination bactérienne sur les surfaces avec une précision de 96,7%. L'étude, réalisée à l'Université McMaster, a été examinée par des pairs et publiée dans 'Advanced Functional Materials' le 30 juillet 2024.
La technologie, dérivée de la nanotechnologie sous licence de FendX, intègre une revêtement de surface changeant de couleur qui passe de bleu à vert-jaune pour indiquer la formation de biofilm bactérien. Grâce à l'apprentissage automatique de l'IA, elle atteint 100% de sensibilité et 95% de précision dans la détection de la contamination.
Carolyn Myers, présidente et PDG de FendX, a souligné le potentiel de cette technologie pour la prévention et le contrôle des infections dans les établissements de santé. L'entreprise a également annoncé la démission d'Andrea Mulder en tant que COO, effective à partir du 30 août 2024.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) hat die Veröffentlichung von Forschungsergebnissen angekündigt, die die Fähigkeit seiner KI-unterstützten Nanotechnologie zeigen, bakterielle Kontaminationen auf Oberflächen mit einer Genauigkeit von 96,7% zu erkennen. Die Studie, die an der McMaster University durchgeführt wurde, wurde von Fachkollegen überprüft und am 30. Juli 2024 in 'Advanced Functional Materials' veröffentlicht.
Die Technologie, die aus der lizenzierten Nanotechnologie von FendX abgeleitet ist, umfasst eine farbwechselnde Oberflächenbeschichtung, die von Blau nach Grün-Gelb wechselt, um die Bildung von bakteriellen Biofilmen anzuzeigen. Mittels KI-Maschinenlernen erzielt sie 100% Sensitivität und 95% Genauigkeit bei der Kontaminationsdetektion.
Carolyn Myers, Präsidentin und CEO von FendX, hob das Potenzial dieser Technologie für Infektionsprävention und -kontrolle in medizinischen Einrichtungen hervor. Das Unternehmen gab außerdem die Rücktritt von Andrea Mulder als COO bekannt, der am 30. August 2024 wirksam wird.
- AI-enhanced nanotechnology demonstrates 96.7% accuracy in detecting bacterial contamination
- Technology achieves 100% sensitivity and 95% accuracy in contamination detection
- Potential application in infection prevention and control in healthcare settings
- Research results published in a peer-reviewed journal
- Resignation of Andrea Mulder as COO effective August 30, 2024
AI-enhanced nanotechnology demonstrated highly reliable pathogen detection
Oakville, Ontario--(Newsfile Corp. - August 13, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection coatings is pleased to announce the publication of results from research conducted at McMaster University demonstrating that its AI-enhanced nanotechnology detects bacterial contamination at
Carolyn Myers, President and CEO of FendX, stated, "This AI-enhanced pathogen detection nanotechnology is derived from of our current nanotechnology licensed from McMaster." Dr. Myers continues, "This technology demonstrated reliable identification of pathogen contamination and with further development may prove beneficial for infection prevention and control in healthcare settings by enabling early contamination detection."
This nanotechnology is an enhancement of FendX's licensed spray formulation covered under the license agreement announced on May 17, 2023, and the collaborative research agreement announced on July 20, 2023. This surface coating, which incorporates bromothymol blue and bromocresol green, transitions from blue to green-yellow to indicate bacterial biofilm formation. For precise contamination detection, it employs AI machine learning that demonstrates
The Company also announces the resignation of Andrea Mulder as COO effective August 30, 2024. The Company would like to thank Ms. Mulder for her service and wishes her well in her future endeavors.
1 https://doi.org/10.1002/adfm.202403157
About FendX Technologies Inc.
FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.
ON BEHALF OF FENDX TECHNOLOGIES INC.
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, President, CEO and Director
1-800-344-9868
investor@fendxtech.com
For more information, please visit https://fendxtech.com/ and the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the nano-spray formulation; statements regarding further development of the nanotechnology; the Company's believe that it may prove beneficial for infection prevention and control in healthcare settings by enabling early contamination detection; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.
Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stage of development; limited operating history; product candidates may require regulatory approvals; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company's public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company's such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219717
FAQ
What is the accuracy rate of FendX's AI-enhanced nanotechnology for detecting bacterial contamination?
Where were the research results for FDXTF's pathogen detection nanotechnology published?
How does FendX's (FDXTF) surface coating technology indicate bacterial contamination?
What is the sensitivity and accuracy of FendX's (FDXTF) AI machine learning for contamination detection?
